Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2015-01-11 Share Issue/Capital Cha…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Appendix 3B - Exercise of Employee Options 14 pages 139.6KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number issued, exercise prices, and terms. It references ASX rules and compliance, and the purpose is clearly related to the announcement of new share issues and application for quotation of additional securities. There is no indication that this is a full financial report, audit, or management discussion. The document is regulatory in nature but specifically focused on capital changes through new share issuance. Therefore, the document fits the category of 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is not a mere announcement of a report but the actual filing of the new issue details.
2015-01-11 English
Commercialisation in US and NovaQuest Dispute Settled 3 pages 167.1KB
Capital/Financing Update Classification · 95% confidence The document is a media release dated 24 December 2014 from Pharmaxis Ltd announcing significant business milestones, including a commercialisation agreement with Chiesi for Bronchitol in the USA and the settlement of a dispute with NovaQuest. The content focuses on business developments, partnership agreements, financing arrangements, and product information. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The document is a corporate announcement about business and financing updates rather than a formal financial report or regulatory filing. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, as the document discusses an amended financing agreement and commercialisation partnership with financial terms.
2014-12-23 English
Appendix 3B - exercise of employee options 14 pages 139.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) announcement used to notify the market of a new issue of securities, application for quotation of additional securities, or agreement related to securities issuance. The text details the issuance of fully paid ordinary shares upon exercise of options under an employee option plan, including the number of securities, exercise prices, and other terms. There is no financial performance data, management discussion, or audit information. The document is not a report but an announcement of a capital change event. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is substantial and contains detailed issuance information, confirming it is not a brief notice or a report publication announcement.
2014-12-01 English
Results of Meeting 2 pages 89.0KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a letter addressed to the Australian Securities Exchange regarding the outcome of resolutions at the Annual General Meeting (AGM) of Pharmaxis Ltd held on 27 November 2014. It details voting results on specific resolutions such as the approval of the remuneration report and the reappointment of a director. The content focuses on the official results of shareholder votes at the AGM, including proxy details and vote counts. There is no indication that this is the full AGM presentation or materials, nor is it a full annual report or financial statement. The document is specifically about the voting results from the AGM, which matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and it is not merely announcing the availability of a report but providing detailed voting outcomes. Therefore, the correct classification is DVA with high confidence.
2014-11-27 English
Chairman's Address to Shareholders 4 pages 116.4KB
AGM Information Classification · 95% confidence The document is titled 'Pharmaxis Ltd Annual General Meeting 27 November 2014 Sydney Chairman’s Address' and contains a detailed speech delivered at the AGM. It discusses company strategy, clinical trials, sales, partnering efforts, cost reductions, and board engagement. The content is typical of presentations and materials shared during an Annual General Meeting, focusing on company updates and shareholder communication rather than detailed financial statements or regulatory filings. There is no indication that this is a full annual report, audit report, or earnings release. The length and detail also exceed a brief announcement or proxy solicitation. Therefore, the document fits best under AGM Information (AGM-R).
2014-11-26 English
2014 AGM Presentation 17 pages 313.2KB
AGM Information Classification · 95% confidence The document is titled 'Annual General Meeting 27 November 2014' and contains sections such as Chairman's Address, Financial Overview, Financial Statements, Shareholder Questions, Formal Business, and detailed voting results for resolutions including adoption of the Remuneration Report and re-election of a director. The content is consistent with materials presented and discussed during an Annual General Meeting (AGM), including financial highlights and shareholder voting outcomes. The presence of proxy vote counts and resolutions further supports this classification. The document length is over 12,000 characters, indicating it is a full presentation or report rather than a brief announcement. Therefore, the document fits the category of AGM Information (AGM-R).
2014-11-26 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.